eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Original paper

Treatment of HCV infection in patients with steatotic liver disease

Robert Flisiak
1
,
Dorota Zarębska-Michaluk
2
,
Krystyna Dobrowolska
3
,
Justyna Janocha-Litwin
4
,
Dorota Dybowska
5
,
Marek Sitko
6
,
Łukasz Socha
7
,
Beata Lorenc
8
,
Jakub Klapaczyński
9
,
Jakub Brodowski
10

  1. Department of Infectious Diseases and Hepatology, Medical University of Białystok, Poland
  2. Department of Infectious Diseases and Allergology, Jan Kochanowski University, Kielce, Poland
  3. Collegium Medicum, Jan Kochanowski University, Kielce, Poland
  4. Department of Infectious Diseases and Hepatology, Wrocław Medical University, Wrocław, Poland
  5. Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
  6. Department of Infectious and Tropical Diseases, Jagiellonian University, Kraków, Poland
  7. Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland
  8. Pomeranian Center of Infectious Diseases, Gdańsk, Poland
  9. Department of Internal Medicine and Hepatology, the National Institute of Medicine of the Ministry of Interior and Administration, Warsaw, Poland
  10. Faculty of Medicine, Medical University of Białystok, Białystok, Poland
Clin Exp HEPATOL 2024; 10, 3
DOI: https://doi.org/10.5114/ceh.2024.141699
Online publish date: 2024/07/23
Article file
- Treatment (1).pdf  [0.10 MB]
Get citation
 
PlumX metrics:
 
1. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58-S68.
2. The Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 2022; 7: 396-415.
3. Sayiner M, Koenig A, Henry L. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 2016; 20: 205-214.
4. Chalasani N, Younossi Z, Lavine JE. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357.
5. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78: 1966-1986.
6. Halota W, Flisiak R, Boroń-Kaczmarska A, et al. Recommendations for the treatment of hepatitis C, Polish Group of HCV Experts -2015. Przegl Epidemiol 2015; 69: 515-521.
7. Halota W, Flisiak R, Boroń-Kaczmarska A, et al. Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts – 2016. Clini Exp Hepatol 2016; 2: 27-33.
8. Halota W, Flisiak R, Juszczyk J, et al. Recommendations for the treatment of hepatitis C in 2017. Clin Exp Hepatol 2017; 3: 47-55.
9. Halota W, Flisiak R, Juszczyk J, et al. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020. Clin Exp Hepatol 2020; 6: 163-169.
10. Tomasiewicz K, Flisiak R, Jaroszewicz J, et al. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023. Clin Exp Hepatol 2023; 9: 1-8.
11. Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol 2020; 73: 1170-1218.
12. Fernandez CJ, Alkhalifah M, Afsar H, et al. Metabolic dysfunction-associated fatty liver disease and chronic viral hepatitis: The interlink. Pathogens 2024; 13: 68.
13. Rafiq N, Younossi ZM. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2008; 2: 207-215.
14. Siphepho PY, Liu YT, Shabangu CS, et al. The impact of steatosis on chronic hepatitis C progression and response to antiviral treatments. Biomedicines 2021; 9: 1491.
15. Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27: 1006-1021.
16. Sanyal AJ. Review article: non‐alcoholic fatty liver disease and hepatitis C – risk factors and clinical implications. Aliment Pharmacol Ther 2005; 22: 48-51.
17. Adinolfi L, Rinaldi L, Guerrera B, et al. NAFLD and NASH in HCV infection: Prevalence and significance in hepatic and extrahepatic manifestations. Int J Mol Sci 2016; 17: 803.
18. Lonardo A. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World J Gastroenterol 2014; 20: 7089.
19. Chang M-L. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol 2016; 22: 1461.
20. Jiang D, Chen C, Liu X, et al. Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis. Ann Transl Med 2021; 9: 1718-1718.
21. Adinolfi L. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
22. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004; 24: 399-413.
23. Gabriel A, Kukla M, Adamek B, et al. Steatosis influences hepatocytes proliferative potential in chronic hepatitis C patients. Pol J Pathol 2018; 69: 388-394.
24. Stan IS, Biciuşcă V, Durand P, et al. Diagnostic and prognostic significance of hepatic steatosis in patients with chronic hepatitis C. Rom J Morphol Embryol 2021; 62: 765-775.
25. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-490.
26. Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J Viral Hepat 2012; 19: 42-47.
27. Kobayashi N, Iijima H, Tada T, et al. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Eur J Gastroenterol Hepatol 2018; 30: 546-551.
Copyright: © 2024 Clinical and Experimental Hepatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.